UPDATE 1-GSK to widen COVID-19 antibody treatment trial after safety clearance
* Interim results expected before year-end* Full efficacy results possible as early as January* Regeneron, Eli Lilly are ahead in antibody race (Adds background on rivals, drug class)By Ludwig BurgerOct 6 (Reuters) - GlaxoSmithKline and partner Vir ...
Read more